Dogwood Therapeutics (DWTX) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 51.6% versus a loss of 77.9%. Over five years, HOWL leads with a -94.7% price change compared with -98.8% for DWTX. Dogwood Therapeutics is the larger company by market cap ($47.9 million vs $44.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DWTX | HOWL |
|---|---|---|
| Share price | $1.41 | $0.91 |
| Market cap | $47.93M | $44.23M |
| 1-day change | -1.40% | -1.10% |
| YTD return | -66.11% | +43.53% |
| 1-year return | -77.90% | -51.60% |
| 5-year return | -98.80% | -94.67% |
| P/E ratio (TTM) | 0.64 | — |
| EPS (TTM) | $2.20 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.04 | $1.94 |
| 52-week low | $1.28 | $0.27 |
| Distance from 52-week high | -79.98% | -53.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +892.91% | +669.23% |
| Average volume | 63.50K | 6.80M |
| Shares outstanding | 33.99M | 48.60M |
| Employees | 8 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed DWTX by 26.3 percentage points over the past year.
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Healthcare · Biotechnology · 8 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Healthcare · Biotechnology · 39 employees
DWTX vs HOWL FAQ
Which is bigger, Dogwood Therapeutics or Werewolf Therapeutics?
Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $47.93M compared with $44.23M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, DWTX or HOWL?
HOWL returned -51.60% over the past 12 months, compared with -77.90% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Are Dogwood Therapeutics and Werewolf Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.